The evolving role of inflammatory biomarkers in risk assessment after stent implantation

Journal of the American College of Cardiology

Volumn 56, Issue 22, 2010, Pages 1783-1793

  Niccoli, Giampaolo ^a   Montone, Rocco A ^a   Ferrante, Giuseppe ^a   Crea, Filippo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLOPIDOGREL; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C5A; DEXAMETHASONE; EOSINOPHIL CATIONIC PROTEIN; FLUINDOSTATIN; GELATINASE A; GELATINASE B; INTERLEUKIN 5; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; PACLITAXEL; PIOGLITAZONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMER; PREDNISONE; PREGNANCY ASSOCIATED PLASMA PROTEIN A; RAPAMYCIN;

ALLERGIC REACTION; ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; BARE METAL STENT; BIODEGRADABLE IMPLANT; CELL MIGRATION; CLINICAL TRIAL; CORONARY STENT; DRUG DOSE REDUCTION; DRUG ELUTING STENT; EOSINOPHIL; EXTRACELLULAR MATRIX; FOREIGN BODY; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; IMPLANTATION; IN-STENT RESTENOSIS; INFLAMMATION; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; STENT THROMBOSIS; VASCULAR SMOOTH MUSCLE;

BIOLOGICAL MARKERS; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; HUMANS; INFLAMMATION; PROGNOSIS; RISK ASSESSMENT; STENTS; THROMBOSIS;

EID: 78449288752     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.06.045     Document Type: Review

References (104)

1. C. Stettler, S. Wandel, and S. Allemann Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis Lancet 370 2007 937 948
2. R. Wessely, A. Kastrati, and A. Schomig Late restenosis in patients receiving a polymer-coated sirolimus-eluting stent Ann Intern Med 143 2005 392 394
3. R. Virmani, F. Liistro, and G. Stankovic Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans Circulation 106 2002 2649 2651
4. R. Virmani, G. Guagliumi, and A. Farb Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109 2004 701 705
5. A.A. Bavry, D.J. Kumbhani, T.J. Helton, P.P. Borek, G.R. Mood, and D.L. Bhatt Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials Am J Med 119 2006 1056 1061
6. R. Kornowski, M.K. Hong, F.O. Tio, O. Bramwell, H. Wu, and M.B. Leon In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia J Am Coll Cardiol 31 1998 224 230
7. A. Farb, G. Sangiorgi, and A.J. Carter Pathology of acute and chronic coronary stenting in humans Circulation 99 1999 44 52
8. S. Cook, E. Ladich, and G. Nakazawa Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis Circulation 120 2009 391 399
9. J.R. Nebeker, R. Virmani, and C.L. Bennett Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project J Am Coll Cardiol 47 2006 175 181
10. D.W. Park, S.C. Yun, and J.Y. Lee C-reactive protein and the risk of stent thrombosis and cardiovascular events after drug-eluting stent implantation Circulation 120 2009 1987 1995
11. K. Toutouzas, A. Colombo, and C. Stefanadis Inflammation and restenosis after percutaneous coronary interventions Eur Heart J 25 2004 1679 1687
12. A. Buffon, G. Liuzzo, and L.M. Biasucci Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty J Am Coll Cardiol 34 1999 1512 1521
13. R.A. Montone, G. Ferrante, M. Baca, and G. Niccoli Predictive value of C-reactive protein after drug-eluting stent implantation Future Cardiol 6 2010 167 179
14. I.M. Chung, H.K. Gold, S.M. Schwartz, Y. Ikari, M.A. Reidy, and T.N. Wight Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment J Am Coll Cardiol 40 2002 2072 2081
15. J. Steffel, F.R. Eberli, T.F. Luscher, and F.C. Tanner Drug-eluting stentswhat should be improved? Ann Med 40 2008 242 252
16. R.A. Byrne, R. Iijima, and J. Mehilli Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer J Am Coll Cardiol Intv 2 2009 291 299
17. D.W. Park, M.K. Hong, and G.S. Mintz Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late "catch-up" phenomenon from ASPECT study J Am Coll Cardiol 48 2006 2432 2439
18. A. Caixeta, M.B. Leon, and A.J. Lansky 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents J Am Coll Cardiol 54 2009 894 902
19. S. Silber, A. Colombo, and A.P. Banning Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions Circulation 120 2009 1498 1504
20. M. Joner, A.V. Finn, and A. Farb Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202
21. J. Steffel, R.A. Latini, and A. Akhmedov Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design Circulation 112 2005 2002 2011
22. B.E. Stahli, G.G. Camici, and J. Steffel Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation Circ Res 99 2006 149 155
23. L.K. Pendyala, X. Yin, J. Li, J.P. Chen, N. Chronos, and D. Hou The first-generation drug-eluting stents and coronary endothelial dysfunction J Am Coll Cardiol Intv 2 2009 1169 1177
24. T.F. Luscher, J. Steffel, and F.R. Eberli Drug-eluting stent and coronary thrombosisbiological mechanisms and clinical implications Circulation 115 2007 1051 1058
25. H.M. van Beusekom, F. Saia, and J.D. Zindler Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus Eur Heart J 28 2007 974 979
26. M. Awata, J. Kotani, and M. Uematsu Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation Circulation 116 2007 910 916
27. A. Chieffo, C. Foglieni, and R.L. Nodari Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents Am J Cardiol 104 2009 1660 1667
28. N. Gonzalo, P.W. Serruys, and T. Okamura Optical coherence tomography patterns of stent restenosis Am Heart J 158 2009 284 293
29. T. Kume, T. Akasaka, and T. Kawamoto Visualization of neointima formation by optical coherence tomography Int Heart J 46 2005 1133 1136
30. T. Higo, Y. Ueda, and J. Oyabu Atherosclerotic and thrombogenic neointima formed over sirolimus drug-eluting stent: an angioscopic study J Am Coll Cardiol Img 2 2009 616 624
31. D. Murakami, M. Takano, and M. Yamamoto Novel neointimal formation over sirolimus-eluting stents identified by coronary angioscopy and optical coherence tomography J Cardiol 53 2009 311 313
32. A. De Labriolle, L. Bonello, and G. Lemesle Clinical presentation and outcome of patients hospitalized for symptomatic in-stent restenosis treated by percutaneous coronary intervention: comparison between drug-eluting stents and bare-metal stents Arch Cardiovasc Dis 102 2009 209 217
33. G.W. Stone, J.W. Moses, and S.G. Ellis Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 2007 998 1008
34. M. Pfisterer, H.P. Brunner-La Rocca, and P.T. Buser Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stentsan observational study of drug-eluting versus bare-metal stents J Am Coll Cardiol 48 2006 2584 2591
35. F. Alfonso, M.J. Perez-Vizcayno, and M. Ruiz Coronary aneurysms after drug-eluting stent implantation: clinical, angiographic, and intravascular ultrasound findings J Am Coll Cardiol 53 2009 2053 2060
36. M.Q. Le, and C.R. Narins Mycotic pseudoaneurysm of the left circumflex coronary artery: a fatal complication following drug-eluting stent implantation Catheter Cardiovasc Interv 69 2007 508 512
37. P.A. Gurbel, K.P. Bliden, R.P. Kreutz, J. Dichiara, M.J. Antonino, and U.S. Tantry The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting Platelets 20 2009 97 104
38. D.J. Kereiakes Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation Circulation 108 2003 III22 III27
39. S. Del Pace, M. Boddi, and R. Rasoini Acute infection-inflammation and coronary stent thrombosis: an observational study Intern Emerg Med 5 2010 121 126
40. W.J. Pichler Delayed drug hypersensitivity reactions Ann Intern Med 139 2003 683 693
41. S. Rathore, M. Terashima, and O. Katoh Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: contemporary practice in real world patients EuroIntervention 5 2009 349 354
42. M.K. Hong, G.S. Mintz, and C.W. Lee Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation Eur Heart J 27 2006 1305 1310
43. P.A. Lemos, A. Hoye, and D. Goedhart Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) study Circulation 109 2004 1366 1370
44. K. Fujii, S.G. Carlier, and G.S. Mintz Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study J Am Coll Cardiol 45 2005 995 998
45. R. Jaffe, and B.H. Strauss Late and very late thrombosis of drug-eluting stents: evolving concepts and perspectives J Am Coll Cardiol 50 2007 119 127
46. C. Gabay, and I. Kushner Acute-phase proteins and other systemic responses to inflammation N Engl J Med 340 1999 448 454
47. P.M. Ridker, N. Rifai, L. Rose, J.E. Buring, and N.R. Cook Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 2002 1557 1565
48. F. Haverkate, S.G. Thompson, S.D. Pyke, J.R. Gallimore, and M.B. Pepys Production of C-reactive protein and risk of coronary events in stable and unstable angina European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group Lancet 349 1997 462 466
49. A. Gaspardone, F. Crea, and F. Versaci Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina Am J Cardiol 82 1998 515 518
50. S. Hoshida, M. Nishino, T. Takeda, J. Tanouchi, Y. Yamada, and M. Hori A persistent increase in C-reactive protein is a risk factor for restenosis in patients with stable angina who are not receiving statins Atherosclerosis 173 2004 285 290
51. A. Segev, S. Kassam, and C.E. Buller Pre-procedural plasma levels of C-reactive protein and interleukin-6 do not predict late coronary angiographic restenosis after elective stenting Eur Heart J 25 2004 1029 1035
52. G. Ferrante, G. Niccoli, and L.M. Biasucci Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients Cardiovasc Revasc Med 9 2008 156 165
53. D.H. Walter, S. Fichtlscherer, M. Sellwig, W. Auch-Schwelk, V. Schachinger, and A.M. Zeiher Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation J Am Coll Cardiol 37 2001 839 846
54. Y.J. Hong, M.H. Jeong, and S.Y. Lim Relation of soft plaque and elevated preprocedural high-sensitivity C-reactive protein levels to incidence of in-stent restenosis after successful coronary artery stenting Am J Cardiol 98 2006 341 345
55. V. Pasceri, J.T. Willerson, and E.T. Yeh Direct proinflammatory effect of C-reactive protein on human endothelial cells Circulation 102 2000 2165 2168
56. J. Zacho, A. Tybjaerg-Hansen, J.S. Jensen, P. Grande, H. Sillesen, and B.G. Nordestgaard Genetically elevated C-reactive protein and ischemic vascular disease N Engl J Med 359 2008 1897 1908
57. R.Y. Zee, H.H. Hegener, A. Fernandez-Cruz, and K. Lindpaintner C-reactive protein gene polymorphisms and the incidence of post-angioplasty restenosis Atherosclerosis 176 2004 393 396
58. A. Gaspardone, F. Versaci, and F. Tomai C-reactive protein, clinical outcome, and restenosis rates after implantation of different drug-eluting stents Am J Cardiol 97 2006 1311 1316
59. J. Ge, C. Shen, C. Liang, L. Chen, J. Qian, and H. Chen Elevated matrix metalloproteinase expression after stent implantation is associated with restenosis Int J Cardiol 112 2006 85 90
60. G.T. Jones, I.P. Kay, and J.W. Chu Elevated plasma active matrix metalloproteinase-9 level is associated with coronary artery in-stent restenosis Arterioscler Thromb Vasc Biol 26 2006 e121 e125
61. X.P. Li, S.H. Zhou, and J.J. Tang Association between plasma pregnancy-associated plasma protein A and restenosis after percutaneous coronary angioplasty Circ J 72 2008 729 733
62. S. Turker, S. Guneri, and B. Akdeniz Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease Am J Cardiol 97 2006 198 202
63. T. Inoue, T. Kato, and Y. Hikichi Stent-induced neutrophil activation is associated with an oxidative burst in the inflammatory process, leading to neointimal thickening Thromb Haemost 95 2006 43 48
64. M. Otsuka, Y. Hayashi, H. Ueda, M. Imazu, and N. Kohno Predictive value of preprocedural fibrinogen concerning coronary stenting Atherosclerosis 164 2002 371 378
65. G. Christ, M. Nikfardjam, and R. Huber-Beckmann Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: dependence on stent implantation and antithrombotic medication J Thromb Haemost 3 2005 233 239
66. M.B. Pepys, and G.M. Hirschfield C-reactive protein: a critical update J Clin Invest 111 2003 1805 1812
67. kip1 promoter activity Circulation 120 2009 669 676
68. L. Hamann, A. Gomma, and N.W. Schroder A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis J Mol Med 83 2005 478 485
69. P.S. Monraats, N.M. Pires, and W.R. Agema Genetic inflammatory factors predict restenosis after percutaneous coronary interventions Circulation 112 2005 2417 2425
70. D.W. Park, C.W. Lee, and S.C. Yun Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation Heart 93 2007 1087 1092
71. A. Dibra, G. Ndrepepa, and J. Mehilli Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents Am J Cardiol 95 2005 1238 1240
72. W.C. Kang, T.H. Ahn, and C.I. Moon Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents Heart 95 2009 970 975
73. K.M. Katsaros, S.P. Kastl, and G. Zorn Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9 J Am Coll Cardiol Intv 3 2010 90 97
74. K.M. Katsaros, W.S. Speidl, and S.P. Kastl Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents J Thromb Haemost 6 2008 508 513
75. W.S. Speidl, K.M. Katsaros, and S.P. Kastl Coronary late lumen loss of drug eluting stents is associated with increased serum levels of the complement components C3a and C5a Atherosclerosis 208 2010 285 289
76. D.H. Choi, K.W. Park, and H.M. Yang Renal dysfunction and high levels of hsCRP are additively associated with hard endpoints after percutaneous coronary intervention with drug eluting stents Int J Cardiol Feb 4 2010 [E-pub ahead of print].
77. C. Delhaye, G. Maluenda, and K. Wakabayashi Long-term prognostic value of preprocedural C-reactive protein after drug-eluting stent implantation Am J Cardiol 105 2010 826 832
78. M. Nakatani, Y. Takeyama, and M. Shibata Mechanisms of restenosis after coronary intervention: difference between plain old balloon angioplasty and stenting Cardiovasc Pathol 12 2003 40 48
79. S.Z. Rittersma, M. Meuwissen, and C.M. van der Loos Eosinophilic infiltration in restenotic tissue following coronary stent implantation Atherosclerosis 184 2006 157 162
80. A.V. Finn, G. Nakazawa, and M. Joner Vascular responses to drug eluting stents: importance of delayed healing Arterioscler Thromb Vasc Biol 27 2007 1500 1510
81. W.J. van der Giessen, A.M. Lincoff, and R.S. Schwartz Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries Circulation 94 1996 1690 1697
82. B.D. Klugherz, G. Llanos, and W. Lieuallen Twenty-eight-day efficacy and pharmacokinetics of the sirolimus-eluting stent Coron Artery Dis 13 2002 183 188
83. G. Niccoli, D. Schiavino, and F. Belloni Pre-intervention eosinophil cationic protein serum levels predict clinical outcomes following implantation of drug-eluting stents Eur Heart J 30 2009 1340 1347
84. H.Y. Mukai, H. Ninomiya, K. Ohtani, T. Nagasawa, and T. Abe Major basic protein binding to thrombomodulin potentially contributes to the thrombosis in patients with eosinophilia Br J Haematol 90 1995 892 899
85. R. Koster, D. Vieluf, and M. Kiehn Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis Lancet 356 2000 1895 1897
86. J. Davignon Beneficial cardiovascular pleiotropic effects of statins Circulation 109 2004 III39 III43
87. V. Pasceri, G. Patti, A. Nusca, C. Pristipino, G. Richichi, and G. Di Sciascio Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study Circulation 110 2004 674 678
88. D.H. Walter, S. Fichtlscherer, and M.B. Britten Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation J Am Coll Cardiol 38 2001 2006 2012
89. P.W. Serruys, P. de Feyter, and C. Macaya Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial JAMA 287 2002 3215 3222
90. A. Gaspardone, F. Versaci, and I. Proietti Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and six-month clinical events Am J Cardiol 90 2002 786 789
91. F. Versaci, A. Gaspardone, and F. Tomai Immunosuppressive Therapy for the Prevention of Restenosis After Coronary Artery Stent Implantation (IMPRESS study) J Am Coll Cardiol 40 2002 1935 1942
92. V. Ferrero, F. Ribichini, A. Rognoni, P. Marino, S. Brunelleschi, and C. Vassanelli Comparison of efficacy and safety of lower-dose to higher-dose oral prednisone after percutaneous coronary interventions (the IMPRESS-LD study) Am J Cardiol 99 2007 1082 1086
93. R. Hoffmann, R. Langenberg, and P. Radke Evaluation of a high-dose dexamethasone-eluting stent Am J Cardiol 94 2004 193 195
94. F. Ribichini, F. Tomai, and L. Paloscia Steroid-eluting stents in patients with acute coronary syndrome: the dexamethasone eluting stent Italian registry Heart 93 2007 598 600
95. C.W. Hwang, D. Wu, and E.R. Edelman Physiological transport forces govern drug distribution for stent-based delivery Circulation 104 2001 600 605
96. T. Takagi, H. Okura, and Y. Kobayashi A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study) J Am Coll Cardiol Intv 2 2009 524 531
97. T. Takagi, A. Yamamuro, and K. Tamita Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study Am Heart J 146 2003 E5
98. E.S. Rosmarakis, and M.E. Falagas Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials Am Heart J 154 2007 144 150
99. K. Dosh, P.B. Berger, and S. Marso Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the Clopidogrel for the Reduction of Events During Observation trial Circ Cardiovasc Interv 2 2009 503 512
100. A. McKay, B.P. Leung, I.B. McInnes, N.C. Thomson, and F.Y. Liew A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma J Immunol 172 2004 2903 2908
101. C. Whatling, W. McPheat, and M. Herslof The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field Expert Opin Investig Drugs 16 2007 1879 1893
102. A. Gershlick, I. De Scheerder, and B. Chevalier Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European Evaluation of Paclitaxel Eluting Stent (ELUTES) trial Circulation 109 2004 487 493
103. R. Erbel, C. Di Mario, and J. Bartunek Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial Lancet 369 2007 1869 1875
104. R. Waksman Promise and challenges of bioabsorbable stents Catheter Cardiovasc Interv 70 2007 407 414